These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38690551)

  • 1. Developing Nepal's medicines pricing policy: evidence synthesis and stakeholders' consultation.
    Babar ZU; Dulal S; Dhakal NP; Upadhyaya MK; Trap B
    J Pharm Policy Pract; 2024; 17(1):2346222. PubMed ID: 38690551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Powers, engagements and resultant influences over the design and implementation of medicine pricing policies in Ghana.
    Koduah A; Baatiema L; Kretchy IA; Agyepong IA; Danso-Appiah A; de Chavez AC; Ensor T; Mirzoev T
    BMJ Glob Health; 2022 May; 7(5):. PubMed ID: 35589156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "What's up with price controls?" Stakeholders' views on the regulation of pharmaceutical pricing in Malaysia.
    Loh YSL; Siah AKL; Koh SGM; Cheong WL; Su TT
    PLoS One; 2023; 18(12):e0291031. PubMed ID: 38060579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
    Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
    Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 6. Overcoming the challenges facing Nepal's health system during federalisation: an analysis of health system building blocks.
    Wasti SP; van Teijlingen E; Rushton S; Subedi M; Simkhada P; Balen J;
    Health Res Policy Syst; 2023 Nov; 21(1):117. PubMed ID: 37919769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs).
    Babar ZU
    Res Social Adm Pharm; 2024 Sep; 20(9):934-939. PubMed ID: 38908991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic Medicine and Generic Prescribing in Nepal: An Implication for Policymakers.
    Shrestha R; Shrestha S; Sapkota B; Thapa S; Ansari M; Khatiwada AP; Roien R; Ozaki A
    J Multidiscip Healthc; 2022; 15():365-373. PubMed ID: 35237042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis.
    Dahmani H; Fradi I; Achour L; Toumi M;
    J Mark Access Health Policy; 2023; 11(1):2244304. PubMed ID: 37614557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
    Puig-Junoy J
    Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of Medicines Pricing Policies in Ghana: The Interplay of Policy Content, Actors' Participation, and Context.
    Koduah A; Baatiema L; Kretchy IA; Agyepong IA; Danso-Appiah A; de Chavez AC; Ensor T; Mirzoev T
    Int J Health Policy Manag; 2023; 12():7994. PubMed ID: 38618785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal Access to Essential Medicines: An Evaluation of Nepal's Free Health Care Scheme.
    Adhikari SR; Pandey AR; Ghimire M; Thapa AK; Lamsal DK
    J Nepal Health Res Counc; 2018 Mar; 16(1):36-42. PubMed ID: 29717287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug retailer training: experiences from Nepal.
    Kafle KK; Gartoulla RP; Pradhan YM; Shrestha AD; Karkee SB; Quick JD
    Soc Sci Med; 1992 Oct; 35(8):1015-25. PubMed ID: 1411696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
    Rand LZ; Kesselheim AS
    Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.